ArticleInternational journal of clinical and experimental medicine2008
The Differential Effects of R580A Mutation on Transamidation and GTP Binding Activity of Rat and Human Type 2 Transglutaminase.
Article in International journal of clinical and experimental medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Distinct conformational states enable transglutaminase 2 to promote cancer cell survival versus cell death.Communications biology · 2024Article
- Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity.Molecular carcinogenesis · 2022Article
- Biochemical Characterisation of Human Transglutaminase 4.International journal of molecular sciences · 2021Article
- Structures of Human Transglutaminase 2: Finding Clues for Interference in Cross-linking Mediated Activity.International journal of molecular sciences · 2020Review
- Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.Molecular cancer research : MCR · 2015Article
- Crystal structure of transglutaminase 2 with GTP complex and amino acid sequence evidence of evolution of GTP binding site.PloS one · 2014Article
- Transglutaminase 2 is secreted from smooth muscle cells by transamidation-dependent microparticle formation.Amino acids · 2012Article
- Using FLIM-FRET to measure conformational changes of transglutaminase type 2 in live cells.PloS one · 2012Article
- Transglutaminase-2: a new endostatin partner in the extracellular matrix of endothelial cells.The Biochemical journal · 2010Article
- Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation.The Journal of biological chemistry · 2010Article
- Intracellular localization and conformational state of transglutaminase 2: implications for cell death.PloS one · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Type 2 transglutaminase (TG2) is an acyltransferase, which also undergoes a GTP-binding/GTPase cycle, with guanine nucleotide and calcium binding reciprocally regulating its transamidation (TG) activity. TG2 is expressed ubiquitously throughout the human body and is the predominant neuronal transglutaminase. Given a postulated role for TG2 in a number of physiological and pathological processes including neurodegenerative diseases, it is of critical importance to understand how TG2 and its enzymatic activities are regulated in the cells. The various aspects of TG2 regulation are addressed by using rat and human TG2 proteins, however, despite their homologous structure, regulation of their enzymatic activities may differ, especially in the cellular context. Here, we evaluate the role of Arg580 in human TG2 and Arg579 in rat TG2 in modulating GTP binding and TG activities in vitro and in situ. We confirm the importance of Arg580 and Arg579 in TG2 for GTP binding as their mutation to Ala completely abolished GTP binding activity in both human (R580A) and rat TG2 (R579A). Next, we showed that in transfected human embryonic kidney (HEK) 293 cells, basal in situ TG activity of human R580A TG2 and rat R579A TG2 was significantly greater than their wild-type (WT) counterparts. However, TG activity of the mutants and WT TG2 became equivalent when the intracellular calcium concentration was maximally increased with maitotoxin. Also, in vitro TG activity assay revealed an intriguing difference between rat and human TG2; at a calcium concentration when their activities were maximum, the protein level of human R580A TG2 was lower than its WT counterpart, whereas rat R579A and WT TG2 protein levels were similar. Taken together, our study underscores an essential role of Arg580 in human TG2 and Arg579 in rat TG2 for their GTP binding ability and also describes for the first time that these amino acid residues differentially influence the TG activity of human or rat TG2 by calcium in vitro and in situ.
Indexed as
Identifiers
19079660PMC2592594W1504273159What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.